{"symbol": "SBIO", "companyName": "ALPS Medical Breakthroughs", "exchange": "NYSE Arca", "industry": "", "website": "http://www.alpsfunds.com", "description": "The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM.\n The fund employs a \"passive management\" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.", "CEO": "", "issueType": "", "sector": "", "tags": []}